Home/FcR Therapeutics/Mark de Boer, PhD

MD

Mark de Boer, PhD

Senior Vice President Corporate Development

FcR Therapeutics

Therapeutic Areas

Autoimmune Diseases

FcR Therapeutics Pipeline

Drug	Indication	Phase
Undisclosed FcR-targeting Nanobody Program(s)	Autoimmune Diseases	Pre-clinical

Leadership Team at FcR Therapeutics

Guido Maertens, MSc

Chief Executive Officer & Chief Financial Officer

Geert van Tetering, PhD

Chief Operating Officer & Chief Scientific Officer

View full FcR Therapeutics profile